XENEXenon Pharmaceuticals Inc.
Is it safe?
Mostly sound, with a caveat: insiders buying, but heavy debt (CCC) and big price swings.
Insiders were net buyers (+$615K, 90 days to Oct 8, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -78% · now 47% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can XENE take a bad year?
The deepest fall in XENE's price history on file is −78%; it is 47% below its high today.
Worst drawdown on file · −47% today
- Cash runway
- 2.8 years
Cash runway · burning $85M a quarter at the current rate
- Annualised volatility
- 58%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $931M
- EBITDA, trailing twelve months
- −$439M
- Operating profit, trailing twelve months
- −$442M
- Annualised volatilitytwo years of daily moves
- 58%
- Worst drawdown on file
- −78%
- Below its 52-week high
- 47%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.